Intellia Therapeutics Inc. (NTLA) Stock: Should Investors Follow These Insider Trades?


Intellia Therapeutics Inc. (NASDAQ:NTLA) saw a downside of -3.19% to $37.30 after subtracting -$1.23 on Wednesday. The 5-day average trading volume is 1,216,273 shares of the company’s common stock. It has gained $38.70 in the past week and touched a new high 3 times within the past 5 days. An average of 1,087,658 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,232,147.

NTLA’s 1-month performance is 6.41% or $1.40 on its low of $32.44 reached on 01/20/23. The company’s shares have touched a 52-week low of $32.44 and high of $104.87, with the stock’s rally to the 52-week high happening on 01/06/23. YTD, NTLA has achieved 10.43% or $1.49 and has reached a new high 4 times. However, the current price is down -64.43% from the 52-week high price.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

NTLA stock investors last saw insider trading activity on Jan 05.Sepp-Lorenzino Laura (EVP, Chief Scientific Officer) most recently sold 2,330 shares at $38.48 per share on Jan 05. This transaction cost the insider $89,659. EVP, General Counsel, BASTA JAMES, sold 1,138 shares at a price of $37.21 on Jan 04. Then, on Jan 04, EVP, Chief Scientific Officer Sepp-Lorenzino Laura sold 2,508 shares at a price of $37.21 per share. This transaction amounted to $93,323.

Valuation Metrics

NTLA stock has a beta of 1.85. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 61.31 while the price-to-book (PB) in the most recent quarter is 3.55.

Intellia Therapeutics Inc.’s quick ratio for the period ended September 29 was 6.60, with the current ratio over the same period at 6.60. The firm’s gross profit as reported stood at $300.9 million against revenue of $33.05 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected NTLA to announce -$1.28 per share in earnings in its latest quarter, but it posted -$1.49, representing a -16.40% surprise. EBITDA for the quarter stood at more than -$103.58 million. NTLA stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 259.51 million, with total debt at $97.65 million. Shareholders hold equity totaling $78.68 million.

Let’s look briefly at Intellia Therapeutics Inc. (NTLA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 48.79% to suggest the stock is trending Neutral, with historical volatility in this time period at 74.56%.

The stock’s 5-day moving average is $35.59, reflecting a +0.83% or $0.30 change from its current price. NTLA is currently trading +4.00% above its 20-day SMA, -39.43% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -31.03% and SMA200 by-44.85%.

Stochastic %K and %D was 63.09% and 45.76% and the average true range (ATR) pointed at 2.35. The RSI (14) points at 46.63%, while the 14-day stochastic is at 55.37% with the period’s ATR at 2.37. The stock’s 9-day MACD Oscillator is pointing at 0.61 and 0.11 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Intellia Therapeutics Inc. (NASDAQ: NTLA), Citigroup upgraded it to a Neutral rating. They previously had a Sell rating on the stock. Analysts offering their rating for NTLA stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate NTLA as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 3 rates the stock as overweight while 20 have offered a “buy” rating.

What is NTLA’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $39.00 and a high of $167.00, with their median price target at $111.00. Looking at these predictions, the average price target given by analysts is for Intellia Therapeutics Inc. (NTLA) stock is $106.16.


Please enter your comment!
Please enter your name here